reports
- Chaima Ferrandon
- Sven Edelfelt
- Carole Braudeau
- Chaima Ferrandon
- Sven Edelfelt
- Carole Braudeau
- Manuel Martin
- CEFA
- CREA
Transactions in connection with share buyback programme
Transactions in connection with share buyback programme Company Announcement Copenhagen, 18 August 2025No. 49/2025 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 20 February 2025 a new share buyback programme, see company announcement no. 12/2025. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also...
- Carole Braudeau
- Carole Braudeau
- Manuel Martin
- CEFA
- CREA
- Manuel Martin
- CEFA
- CREA
- Manuel Martin
- CEFA
- CREA
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Ind...
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older Saint Herblain (France), August 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252. In addit...
Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé ...
Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus Saint-Herblain (France), le 18 août 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à dose unique, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya chez les personnes âgées de 12 ans et plus. Cette annonce s'ajoute à l'autorisation de mise sur le marché déjà obtenue au Canada pour les adultes1 et fait...
- Maissa Keskes
- Stephane Houri
EVT EVOTEC SE
GYC GRAND CITY PROPERTIES SA
TPE PVA TEPLA AG
GLB GLANBIA PLC
LNZ LENZING AG
SIX2 SIXT SE
FTON FEINTOOL INTERNATIONAL HOLDING AG
WIE WIENERBERGER AG
SEM SEMPERIT HOLDING AG
PAT PATRIZIA AG
KTCG KAPSCH TRAFFICCOM
FYB FORMYCON AG
JEN JENOPTIK AG
HGEA HGEARS AG
TUI TUI AG
R3NK RENK GROUP AG
AQ AQUILA PART PROD COM
SPG SPRINGER NATURE AG & CO. KGAA
- Maissa Keskes
- Stephane Houri
EVT EVOTEC SE
GYC GRAND CITY PROPERTIES SA
TPE PVA TEPLA AG
GLB GLANBIA PLC
LNZ LENZING AG
SIX2 SIXT SE
FTON FEINTOOL INTERNATIONAL HOLDING AG
WIE WIENERBERGER AG
SEM SEMPERIT HOLDING AG
PAT PATRIZIA AG
KTCG KAPSCH TRAFFICCOM
FYB FORMYCON AG
JEN JENOPTIK AG
HGEA HGEARS AG
TUI TUI AG
R3NK RENK GROUP AG
AQ AQUILA PART PROD COM
SPG SPRINGER NATURE AG & CO. KGAA
- Martijn Den Drijver
- Olfa Taamallah
- Yan Derocles
- Olfa Taamallah
- Yan Derocles
- ABGSC Services Research
- Mikkel Løgsted
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.